ArticleJournal of medical virology2026
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2/KDR) Promotes KSHV Lytic Replication and Drives Pro-Inflammatory Cytokine Release and Cancer Signaling.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Expression of vascular endothelial growth factor receptor 2 (VEGFR2/KDR) is elevated in Kaposi Sarcoma lesions and is a key driver of vasculogenesis and angiogenesis. Increased levels of KDR are associated with several cancers and has been linked to the oncogenic potential of Kaposi sarcoma herpesvirus (KSHV)-infected cells. However, the functional role of KDR in KSHV infection requires further exploration. Here, we have demonstrated the importance of KDR expression in KSHV infection and assessed the effects of KDR loss-of-function in KSHV lytic replication and the corresponding host response in de novo infected primary lymphatic endothelial cells (LEC). KDR was found to promote lytic replication, stimulate the release of pro-inflammatory cytokines, and upregulate cancer signaling pathways. As such, we propose a model in which elevated KDR in KS lesions supports a lytic program to ensure maintenance and spread of infected cells while also promoting the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.